Home / Therapeutic Area / Colorectal Cancer Drug Development Pipeline Review, 2017

Colorectal Cancer Drug Development Pipeline Review, 2017

Published: Sep 2017 | Published By: GBI Research

Description

This report provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.

Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason.

The size of these pipelines ranges from 10 products in rectal cancer to 581 products in colorectal cancer. Across all three of these indications, however, kinases, immune-related proteins, DNA-related proteins and viral proteins are common targets, closely reflecting the current treatment landscape of these diseases.

Scope

  • Which companies are the most active within the pipeline for colorectal cancer therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Reasons To Buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Executive Summary

3 Introduction
3.1 GBI Research Report Coverage
3.2 Anal Cancer – Overview
3.3 Rectal Cancer – Overview
3.4 Colorectal Cancer – Overview3.5 GBI Research Report Guidance

4 Therapeutics Development
4.1 Anal Cancer
4.1.1 Pipeline Overview
4.1.2 Pipeline by Companies
4.1.3 Products under Development by Companies
4.2 Rectal Cancer
4.2.1 Pipeline Overview
4.2.2 Pipeline by Companies
4.2.3 Products under Development by Companies
4.3 Colorectal Cancer
4.3.1 Pipeline Overview
4.3.2 Pipeline by Companies
4.3.3 Pipeline by Universities/Institutes
4.3.4 Products under Development by Companies
4.3.5 Products under Development by Universities/Institutes

5 Therapeutics Assessment
5.1 Anal Cancer
5.1.1 Assessment by Target
5.1.2 Assessment by Mechanism of Action
5.1.3 Assessment by Route of Administration
5.1.4 Assessment by Molecule Type
5.2 Rectal Cancer
5.2.1 Assessment by Target
5.2.2 Assessment by Mechanism of Action
5.2.3 Assessment by Route of Administration
5.2.4 Assessment by Molecule Type
5.3 Colorectal Cancer
5.3.1 Assessment by Target
5.3.2 Assessment by Mechanism of Action
5.3.3 Assessment by Route of Administration
5.3.4 Assessment by Molecule Type

6 Companies Involved in Therapeutics Development
6.1 Anal Cancer
6.1.1 Advaxis Inc
6.1.2 Amgen Inc
6.1.3 Atara Biotherapeutics Inc
6.1.4 Bayer AG
6.1.5 BeiGene Ltd
6.1.6 Eli Lilly and Company
6.1.7 Immunovaccine Inc
6.1.8 ISA Pharmaceuticals BV
6.1.9 Merck & Co Inc
6.1.10 Ono Pharmaceutical Co Ltd
6.1.11 Oryx GmbH & Co KG
6.1.12 PDS Biotechnology Corp
6.1.13 Sun Pharma Advanced Research Company Ltd
6.1.14 Taiwan Liposome Company Ltd
6.2 Rectal Cancer
6.2.1 AbbVie Inc
6.2.2 Advaxis Inc
6.2.3 Eisai Co Ltd
6.2.4 GlaxoSmithKline Plc
6.2.5 Karyopharm Therapeutics Inc
6.2.6 Madrigal Pharmaceuticals Inc.
6.2.7 NewLink Genetics Corp
6.2.8 Peregrine Pharmaceuticals Inc
6.2.9 Regeneron Pharmaceuticals Inc
6.2.10 Taiwan Liposome Company Ltd
6.3 Colorectal Cancer
6.3.1 2cureX ApS
6.3.2 3-V Biosciences Inc
6.3.3 3SBio Inc
6.3.4 4SC AG
6.3.5 AB Science SA
6.3.6 AbbVie Inc
6.3.7 AbGenomics International Inc
6.3.8 Aclaris Therapeutics Inc
6.3.9 Adamed Sp z oo
6.3.10 Aduro BioTech Inc
6.3.11 Advenchen Laboratories LLC
6.3.12 Allinky Biopharma
6.3.13 amcure GmbH
6.3.14 Amgen Inc
6.3.15 Antibe Therapeutics Inc
6.3.16 APEIRON Biologics AG
6.3.17 Apexigen Inc
6.3.18 Aphios Corp
6.3.19 Aposense Ltd
6.3.20 ARMO Biosciences Inc
6.3.21 ArQule Inc
6.3.22 Array BioPharma Inc
6.3.23 Asana BioSciences LLC
6.3.24 Aslan Pharmaceuticals Pte Ltd
6.3.25 Astellas Pharma Inc
6.3.26 Astex Pharmaceuticals Inc
6.3.27 AstraZeneca Plc
6.3.28 Aurobindo Pharma Ltd
6.3.29 AVEO Pharmaceuticals Inc
6.3.30 B Cell Design SAS
6.3.31 Basilea Pharmaceutica Ltd
6.3.32 Bavarian Nordic A/S
6.3.33 Bayer AG
6.3.34 BeiGene Ltd
6.3.35 Beijing Hanmi Pharmaceutical Co Ltd
6.3.36 BeyondSpring Pharmaceuticals Inc
6.3.37 Biocon Ltd
6.3.38 Bionomics Ltd
6.3.39 Bionovis SA
6.3.40 Biotecnol Ltd
6.3.41 Biothera Pharmaceutical Inc
6.3.42 Boehringer Ingelheim GmbH
6.3.43 Boston Biomedical Inc
6.3.44 Bristol-Myers Squibb Company
6.3.45 Calithera Biosciences Inc
6.3.46 Cancer Prevention Pharmaceuticals Inc
6.3.47 Cantargia AB
6.3.48
6.3.49 Carna Biosciences Inc
6.3.50 Cascadian Therapeutics Inc
6.3.51 CBT Pharmaceuticals Inc
6.3.52 CCRP Therapeutics GmbH
6.3.53 Celgene Corp
6.3.54 Celldex Therapeutics Inc
6.3.55 Cellectar Biosciences Inc
6.3.56 Celleron Therapeutics Ltd
6.3.57 Celltrion Inc
6.3.58 Celyad SA
6.3.59 Chipscreen Biosciences Ltd
6.3.60 ChoDang Pharm Co Ltd
6.3.61 Chong Kun Dang Pharmaceutical Corp
6.3.62 Cleave Biosciences Inc
6.3.63 Cleveland BioLabs Inc
6.3.64 COARE Biotechnology Inc
6.3.65 Coherus BioSciences Inc
6.3.66 Compugen Ltd
6.3.67 Conatus Pharmaceuticals Inc
6.3.68 Corvus Pharmaceuticals Inc
6.3.69 Critical Outcome Technologies Inc
6.3.70 CrystalGenomics Inc
6.3.71 Daiichi Sankyo Company Ltd
6.3.72 DanDrit Biotech A/S
6.3.73 Deciphera Pharmaceuticals LLC
6.3.74 Dr. Reddy's Laboratories Ltd
6.3.75 eFFECTOR Therapeutics Inc
6.3.76 Eisai Co Ltd
6.3.77 Eli Lilly and Co
6.3.78 Endor Nanotechnologies SL
6.3.79
6.3.80 Ensol Biosciences Inc
6.3.81 EntreChem SL
6.3.82 Enzene Biosciences Ltd
6.3.83 Enzo Biochem Inc
6.3.84 EpiThany Inc
6.3.85 Etubics Corp
6.3.86 Exelixis Inc
6.3.87 Exicure Inc
6.3.88 F-star Biotechnology Ltd
6.3.89 F. Hoffmann-La Roche Ltd
6.3.90 Formosa Laboratories Inc
6.3.91 Forty Seven Inc
6.3.92 Fusion Antibodies Ltd
6.3.93 Gene Techno Science Co Ltd
6.3.94 Genentech Inc
6.3.95 Genor BioPharma Co Ltd
6.3.96 Genoscience Pharma
6.3.97 Genzyme Corp
6.3.98 Gilead Sciences Inc
6.3.99 GlaxoSmithKline Plc
6.3.100 Glenmark Pharmaceuticals Ltd
6.3.101 Glycostem Therapeutics BV
6.3.102 Glycotope GmbH
6.3.103 Green Cross Corp
6.3.104 Handok Inc
6.3.105 Hanmi Pharmaceuticals Co Ltd
6.3.106 Heat Biologics Inc
6.3.107 Hemispherx Biopharma Inc
6.3.108 Humanigen Inc
6.3.109 Humorigin Biotechnology Corp
6.3.110 Hutchison MediPharma Ltd
6.3.111 iDD biotech SAS
6.3.112 Ideaya Biosciences Inc
6.3.113 Ignyta Inc
6.3.114 Ildong Pharmaceutical Co Ltd
6.3.115 Immodulon Therapeutics Ltd
6.3.116 ImmuneXcite Inc
6.3.117 Immunomedics Inc
6.3.118 Immunovative Therapies Ltd
6.3.119 Incanthera Ltd
6.3.120 Incyte Corp
6.3.121 Innovation Pharmaceuticals Inc
6.3.122 Innovent Biologics Inc
6.3.123 Inovio Pharmaceuticals Inc
6.3.124 Interprotein Corp
6.3.125 Intezyne Technologies Inc
6.3.126 Ionis Pharmaceuticals Inc
6.3.127 Isofol Medical AB
6.3.128 Jeil Pharmaceutical Co Ltd
6.3.129 JHL Biotech Inc
6.3.130 Jiangsu Hengrui Medicine Co Ltd
6.3.131 Johnson & Johnson
6.3.132 Kancera AB
6.3.133 Karyopharm Therapeutics Inc
6.3.134 Kura Oncology Inc
6.3.135 Laboratorio ELEA SACIF y A
6.3.136 LipoMedix Pharmaceutical Inc
6.3.137 Loxo Oncology Inc
6.3.138 Luye Pharma Group Ltd
6.3.139 Mabion SA
6.3.140 MacroGenics Inc
6.3.141 Mantis Therapeutics BV
6.3.142 Marina Biotech Inc
6.3.143 Medesis Pharma SA
6.3.144 MediaPharma SRL
6.3.145 MedImmune LLC
6.3.146 Medinet Co Ltd
6.3.147 Medivir AB
6.3.148 Merck & Co Inc
6.3.149 Merck KGaA
6.3.150 Merrimack Pharmaceuticals Inc
6.3.151 Merus NV
6.3.152 Microlin Bio Inc
6.3.153 Millennium Pharmaceuticals Inc
6.3.154 Molecular Partners AG
6.3.155 MolMed SpA
6.3.156 Mologen AG
6.3.157 Morphotek Inc
6.3.158 Multimmune GmbH
6.3.159 Mycenax Biotech Inc
6.3.160 NantKwest Inc
6.3.161 Natco Pharma Ltd
6.3.162 NatureWise Biotech & Medicals Corp
6.3.163 Nektar Therapeutics
6.3.164 Neovacs SA
6.3.165 Nerviano Medical Sciences Srl
6.3.166 Nippon Kayaku Co Ltd
6.3.167 NormOxys Inc
6.3.168 Northwest Biotherapeutics Inc
6.3.169 Novartis AG
6.3.170 Novogen Ltd
6.3.171 Noxxon Pharma AG
6.3.172 NuCana BioMed Ltd
6.3.173 OBI Pharma Inc
6.3.174 Omnitura Therapeutics Inc
6.3.175 Oncobiologics Inc
6.3.176 Oncology Research International Ltd
6.3.177 Oncolytics Biotech Inc
6.3.178 OncoMed Pharmaceuticals Inc
6.3.179 Onconova Therapeutics Inc
6.3.180 Ono Pharmaceutical Co Ltd
6.3.181 Oryx GmbH & Co KG
6.3.182 Otsuka Holdings Co Ltd
6.3.183 Oxford BioMedica Plc
6.3.184 Pfizer Inc
6.3.185 Pharma Mar SA
6.3.186 PharmAbcine Inc
6.3.187 Pivotal BioSciences Inc
6.3.188 PlantForm Corp
6.3.189 Plexxikon Inc
6.3.190 PLx Pharma Inc
6.3.191 Precision Biologics Inc
6.3.192 Propanac Biopharma Inc
6.3.193 Provectus Biopharmaceuticals Inc
6.3.194 PsiOxus Therapeutics Ltd
6.3.195 Puma Biotechnology Inc
6.3.196 Puretech Health plc
6.3.197 R Pharm
6.3.198 Rafael Pharmaceuticals Inc
6.3.199 RedHill Biopharma Ltd
6.3.200 Redx Pharma Plc
6.3.201 Rexahn Pharmaceuticals Inc
6.3.202 Rgenix Inc
6.3.203 Rhizen Pharmaceuticals SA
6.3.204 Richter Gedeon Nyrt
6.3.205 Samumed LLC
6.3.206 Sanofi
6.3.207 Selvita SA
6.3.208 Siamab Therapeutics Inc
6.3.209 Sichuan Kelun Pharmaceutical Co Ltd
6.3.210 Sigma-Tau SpA
6.3.211 Sigmoid Pharma Ltd
6.3.212 Sillajen Biotherapeutics
6.3.213 Simcere Pharmaceutical Group
6.3.214 Sorrento Therapeutics Inc
6.3.215 Steba Biotech SA
6.3.216 Sumitomo Dainippon Pharma Co Ltd
6.3.217 SuviCa Inc
6.3.218 Symphogen A/S
6.3.219 SynDevRx Inc
6.3.220 Synermore Biologics Co Ltd
6.3.221 Taiho Pharmaceutical Co Ltd
6.3.222 TaiwanJ Pharmaceuticals Co Ltd
6.3.223 Takeda Pharmaceutical Co Ltd
6.3.224 Targovax ASA
6.3.225 Tarrex Biopharma Ltd
6.3.226 Tarveda Therapeutics Inc
6.3.227 tella Inc
6.3.228 Tiltan Pharma Ltd
6.3.229 Tocagen Inc
6.3.230 TRACON Pharmaceuticals Inc
6.3.231 Transgene SA
6.3.232 United BioPharma Inc
6.3.233 Vaccinex Inc
6.3.234 VasGene Therapeutics Inc
6.3.235 Vaximm AG
6.3.236 ViiV Healthcare Ltd
6.3.237 Vitality Biopharma Inc
6.3.238 Wellstat Biologics Corp
6.3.239 Wilex AG
6.3.240 WntResearch AB
6.3.241 Wuhan YZY Biopharma Co Ltd
6.3.242 XBiotech Inc
6.3.243 XuanZhu Pharma Co Ltd
6.3.244 Yabao Pharmaceutical Group Co Ltd
6.3.245 Zymeworks Inc

7 Dormant Projects
7.1 Anal Cancer
7.2 Rectal Cancer
7.3 Colorectal Cancer

8 Discontinued Products
8.1 Anal Cancer
8.2 Colorectal Cancer

9 Product Development Milestones
9.1 Anal Cancer
9.1.1 Featured News & Press Releases
9.2 Rectal Cancer
9.2.1 Featured News & Press Releases
9.3 Colorectal Cancer
9.3.1 Featured News & Press Releases

10 Appendix
10.1 Methodology
10.2 Coverage
10.3 Secondary Research
10.4 Primary Research
10.5 Expert Panel Validation
10.6 Contact Us
10.7 Disclaimer

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +